The iontophoretic transdermal system formulation of sumatriptan as a new option in the acute treatment of migraine: a perspective

Magnetically triggered release of amoxicillin from xanthan/Fe3O4/albumin patches

This work was motivated by the need of stimuli responsive drug carriers, which can be activated by low cost non-invasive stimuli such as external magnetic field (EMF). Thus, novel antimicrobial materials based on xanthan gum (XG), magnetic nanoparticles (MNP), bovine serum albumin (BSA) and amoxicillin (Amox) were designed in order to promote the release of Amox under magnetic stimuli. Firstly, surfaces with different functionalities were prepared by sequential deposition of thin layers on Si wafers and characterized by means of ellipsometry and atomic force microscopy. Amox adsorbed preferentially onto XG or BSA films. In solution, favorable interactions between Amox and BSA were evidenced by substantial changes in the BSA secondary structure, as revealed by circular dichroism. Patches of XG and XG/MNP/BSA were immersed in 2 g L^-1 Amox, yielding 10 ± 3 and 17 ± 4 μg/cm³ Amox loading, respectively. The inclusion of 0.2 wt% Fe₃O₄ in the patches and their exposure to EMF enabled in vitro release of Amox, at pH 5.5 and 0.02 mol L^-1 NaCl, following the quasi-Fickian behavior. Amox diffused from XG/MNP/BSA patches in agar medium containing Staphylococcus aureus and Escherichia coli, inhibiting their growth. The inhibition of E. coli growth was particularly efficient under EMF.

Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients

Background

Migraine pain relief is reported by more than 50% of patients who receive low dose (3 mg) of sumatriptan. Currently, there is no two-step autoinjector of low-dose sumatriptan available on the market for acute migraine treatment. To fulfill this need, a fully assembled, single-dose, subcutaneous autoinjector (sumatriptan 3 mg; product-code DFN-11) was developed. The device allows for injection with a simple two-step, push-to-inject process and provides feedback of the injection activation, progress, and completion.

Objective

To determine if DFN-11 autoinjector can be used correctly and safely by migraine patients.

Methods and participants

A human factors validation study was conducted with 45 migraine patients (30 oral-only medications users; 15 injectable sumatriptan users) who performed one unaided simulated injection. Two days prior, half the oral participants were briefly trained. All others were only given the device to inspect and written instructions to review. No injections were performed during the initial session. All participants received written instructions at the injection session.

Results

All participants (45/45; 100%) performed the injection without any errors. Objective measures included device removal from packaging, cap removal, expiration date check, inspection of fluid in window, identification of allowable injection site, proper device positioning, dose confirmation, and device disposal. All participants (45/45; 100%) reported no difficulty administering the injection and no concerns about using the autoinjector during a severe migraine onset.

Conclusion

The results showed that the DFN-11 autoinjector can be used with safe handling without patterns of confusion, failures, high-risk errors, wet injections, or patient safety risks. The DFN-11 autoinjector was validated to be used correctly and safely by migraine patients, whether they were injection experienced, unexperienced, trained, or self-trained.